Abiraterone treatment of metastatic hormone sensitive prostate cancer
DOI: 10.22591/magyurol.2023.3.rieszp.142
Authors:
Riesz Péter dr., Nyirády Péter dr.
Semmelweis Egyetem Urológiai Klinika és Uroonkológiai Centrum, Budapest (igazgató: Nyirády Péter dr.)
Summary
Prostate cancer is the most common urological malignancy in man. It is often discovered in its metastatic form when the focus is on medical treatments. For decades, androgen deprivation therapy has been the first step in the treatment of metastatic prostate cancer, which is based on the hormone sensitivity of cancer cells. In this so-called hormone-sensitive state, a complete survival advantage was first demonstrated with early docetaxel chemotherapy given in addition to ADT, and with the introduction of new
types of hormone therapies. New types of hormone therapy include abirateron acetate by inhibiting steroid synthesis. The authors aimed to describe the indication, course, benefits and side effects of abiraterone treatment in metastatic hormone-
sensitive prostate cancer. Today, in case of metastatic prostate cancer, combination treatments are the standard first-line therapy (ADT + chemotherapy + new type of hormone therapy), so useful information for all practicing urologists is provided in the article.